Role of fecal DNA level of Fusobacterium nucleatum and clbA+ Escherichia coli in the diagnosis of colorectal cancer

doi:10.3969/j.issn.1673-8640.2020.04.006

Abstract

Abstract:

Objective To investigate the role of fecal DNA level of Fusobacterium nucleatum and clbA+ Escherichia coli in the diagnosis of colorectal cancer. Methodse Real-time fluorescence quantitation polymerase chain reaction（PCR） was used to determine the DNA level of Fusobacterium nucleatum and clbA+Escherichia coli in 58 healthy subjects,38 adenoma patients and 115 colorectal cancer patients. Results The DNA levels of clbA+ Escherichia coli were 0.001 6（0.000 46-0.004 9） in healthy control group,0.002 6（0.000 45-0.008 8） in adenoma group and 0.006 3（0.002 0-0.036） in colorectal cancer group. Those of Fusobacterium nucleatum were 0.001 0（0.000 31-0.002 9）in healthy control group,0.003 3（0.001 1-0.011 0） in adenoma group and 0.006 4（0.002 9-0.012 0） in colorectal cancer group. The DNA level of Fusobacterium nucleatum and clbA+Escherichia coli in colorectal cancer group had statistical significance compared with healthy control group（P<0.000 1）. Receiver operating characteristic（ROC） curve analysis showed that the areas under curves（AUC）of clbA+ Escherichia coli and Fusobacterium nucleatum in the diagnosis of colorectal cancer were 0.712 and 0.750,respectively. The optimal cut-off values were 0.003 3 and 0.002 3,the sensitivities were 64.32% and 80.87%,and the specificities were 65.52% and 68.97%,respectively. The positive rates of clbA+ Escherichia coli and Fusobacterium nucleatum in the early stage of colorectal cancer were 75.7% and 80.5%,which were higher than those of carcinoembryonic antigen（CEA） and fecal occult blood test（FOBT）,and there was no statistical significance between early and advanced stages（P>0.05）. Conclusions The clbA+ Escherichia coli and Fusobacterium nucleatum are abundant in feces from colorectal cancer patients,which may be used as potential early determination biomarkers in colorectal cancer.

Key words: Fusobacterium nucleatum, clbA+Escherichia coli, Biomarker, Feces, Colorectal cancer

CLC Number:

R379.9

LIU Yan, LONG Yin, PAN Weijie, ZHANG Tong, WENG Wenhao, YU Ying. Role of fecal DNA level of Fusobacterium nucleatum and clbA+ Escherichia coli in the diagnosis of colorectal cancer[J]. Laboratory Medicine, 2020, 35(4): 314-317.

Figures/Tables 3

References 14.

1.	CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
2.	NOUGAYRÈDE J P,HOMBURG S,TAIEB F,et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells[J]. Science,2006,313(5788):848-851.
3.	ZHANG S,CAI S,MA Y.Association between Fusobacterium nucleatum and colorectal cancer:progress and future directions[J]. J Cancer,2018,9(9):1652-1659.
4.	YANG Y,WENG W,PENG J,et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factor-κB,and up-regulating expression of microRNA-21[J]. Gastroenterology,2017,152(4):851-866.e24.
5.	YU T,GUO F,YU Y,et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell,2017,170(3):548-563.e16.
6.	LADABAUM U,DOMINITZ J A,KAHI C,et al.Strategies for colorectal cancer screening[J]. Gastroenterology,2020,158(2):418-432.
7.	SONG L L,LI Y M.Current noninvasive tests for colorectal cancer screening: an overview of colorectal cancer screening tests[J]. World J Gastrointest Oncol,2016,8(11):793-800.
8.	LI J N,YUAN S Y.Fecal occult blood test in colorectal cancer screening[J]. J Dig Dis,2019,20(2):62-64.
9.	SUBRAMANIAN S,TANGKA F K SL,HOOVER SS,et al. Costs of colorectal cancer screening provision in CDC's Colorectal Cancer Control Program:comparisons of colonoscopy and FOBT/FIT based screening[J]. Eval Program Plann,2017,62:73-80.
10.	SARASTE D,MARTLING A,NILSSON P J,et al.Complications after colonoscopy and surgery in a population-based colorectal cancer screening programme[J]. J Med Screen,2016,23(3):135-140.
11.	TJALSMA H,BOLEIJ A,MARCHESI J R,et al.A bacterial driver-passenger model for colorectal cancer:beyond the usual suspects[J]. Nat Rev Microbiol,2012,10(8):575-582.
12.	CUEVAS-RAMOS G,PETIT C R,MARCQ I,et al.Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells[J]. Proc Natl Acad Sci U S A,2010,107(25):11537-11542.
13.	ABED J,EMGÅRD J E,ZAMIR G,et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc[J]. Cell Host Microbe,2016,20(2):215-225.
14.	WACHSMANNOVA L,MEGO M,STEVURKOVA V,et al.Novel strategies for comprehensive mutation screening of the APC gene[J]. Neoplasma,2017,64(3):338-343.

组别	例数	clbA+大肠埃希菌	具核梭杆菌
肠癌组	115	0.006 3（0.002 0~0.036 0）^**##	0.006 4（0.002 9~0.012 0）^**#
腺瘤组	38	0.002 6（0.000 45~0.008 8）	0.003 3（0.001 1~0.011 0）^*
健康对照组	58	0.001 6（0.000 46~0.004 9）	0.001 0（0.000 31~0.002 9）

组别	例数	clbA+大肠埃希菌	具核梭杆菌
肠癌组	115	0.006 3（0.002 0~0.036 0）^**##	0.006 4（0.002 9~0.012 0）^**#
腺瘤组	38	0.002 6（0.000 45~0.008 8）	0.003 3（0.001 1~0.011 0）^*
健康对照组	58	0.001 6（0.000 46~0.004 9）	0.001 0（0.000 31~0.002 9）

组别	例数	clbA+大肠埃希菌DNA	具核梭杆菌DNA	clbA+大肠埃希菌DNA与具核梭杆菌DNA联合	CEA	FOBT
早期肠癌组	87	54（75.7）	70（80.5）	71（81.6）	22（25.3）	44（50.6）
晚期肠癌组	28	20（71.4）	23（82.1）	22（78.6）	15（53.6）	14（50.1）
χ²值		0.452 0	0.006 0	0.006 0	6.523 0	0.027 0
P值		0.501 2	0.936 8	0.936 8	0.010 6	0.869 4

组别	例数	clbA+大肠埃希菌DNA	具核梭杆菌DNA	clbA+大肠埃希菌DNA与具核梭杆菌DNA联合	CEA	FOBT
早期肠癌组	87	54（75.7）	70（80.5）	71（81.6）	22（25.3）	44（50.6）
晚期肠癌组	28	20（71.4）	23（82.1）	22（78.6）	15（53.6）	14（50.1）
χ²值		0.452 0	0.006 0	0.006 0	6.523 0	0.027 0
P值		0.501 2	0.936 8	0.936 8	0.010 6	0.869 4

[1]	LI Liangshan, ZHAO Hu, WANG Shiwen. Screening potential prognostic biomarkers of colorectal cancer based on weighted gene co-expression network analysis [J]. Laboratory Medicine, 2023, 38(9): 825-832.
[2]	SUN Zepeng, WANG Hongbin, WANG Jiandong, SONG Dewei, XIAO Peng. Analysis and progress of peptide and protein biomarker methodology for myocardial injury [J]. Laboratory Medicine, 2023, 38(8): 784-789.
[3]	ZHU Rixiang, YIN Jie. Relationship between soluble growth stimulating gene 2 protein and clinicopathological features and prognosis in patients with colorectal cancer [J]. Laboratory Medicine, 2023, 38(7): 629-633.
[4]	ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598.
[5]	GAO Feng. Clinical application of novel tumor biomarkers：prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306.
[6]	JIANG Mengying, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, DU Yan. Clinical role of serum S1P in the early diagnosis of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 307-312.
[7]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Roles of serum HYAL1 and HA in the auxiliary diagnosis and therapeutic monitoring of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 313-319.
[8]	YANG Jielin, WANG Xiaoyuan, LI Haixia. Expression and interaction of TRX and TXNIP in colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 330-336.
[9]	ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210.
[10]	LU Qiyuan, LU Jianhua. Biomarker research progress for the diagnosis of periprosthetic joint infection [J]. Laboratory Medicine, 2023, 38(10): 997-1002.
[11]	CHEN Xuewei, LI Yirong. Candidate biomarkers in metabolic syndrome based on GEO database [J]. Laboratory Medicine, 2023, 38(1): 32-38.
[12]	WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99.
[13]	WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 877-881.
[14]	WU Yanqian, YU Chong, SHEN Lu, ZHENG Haoran, HONG Yeting. Research progress of body fluid piRNA as a potential biomarker of disease [J]. Laboratory Medicine, 2022, 37(8): 782-786.
[15]	ZHU Yunjie, MA Zhengyao, SHEN Minna, ZHOU Yan, HUANG Fei, CHEN Xinning, ZHANG Chunyan, WANG Beili, GUO Wei. Establishment and clinical application evaluation of plasma cfDNA determination in colorectal cancer patients [J]. Laboratory Medicine, 2022, 37(6): 561-567.